Your browser doesn't support javascript.
loading
Model averaging for treatment effect estimation in subgroups.
Bornkamp, Björn; Ohlssen, David; Magnusson, Baldur P; Schmidli, Heinz.
Affiliation
  • Bornkamp B; Novartis Pharma AG, Basel, CH-4002, Switzerland.
  • Ohlssen D; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 07936-1080, USA.
  • Magnusson BP; Novartis Pharma AG, Basel, CH-4002, Switzerland.
  • Schmidli H; Novartis Pharma AG, Basel, CH-4002, Switzerland.
Pharm Stat ; 16(2): 133-142, 2017 03.
Article in En | MEDLINE | ID: mdl-27935199
ABSTRACT
In many clinical trials, biological, pharmacological, or clinical information is used to define candidate subgroups of patients that might have a differential treatment effect. Once the trial results are available, interest will focus on subgroups with an increased treatment effect. Estimating a treatment effect for these groups, together with an adequate uncertainty statement is challenging, owing to the resulting "random high" / selection bias. In this paper, we will investigate Bayesian model averaging to address this problem. The general motivation for the use of model averaging is to realize that subgroup selection can be viewed as model selection, so that methods to deal with model selection uncertainty, such as model averaging, can be used also in this setting. Simulations are used to evaluate the performance of the proposed approach. We illustrate it on an example early-phase clinical trial.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Models, Statistical / Bayes Theorem Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2017 Type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Models, Statistical / Bayes Theorem Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Pharm Stat Journal subject: FARMACOLOGIA Year: 2017 Type: Article Affiliation country: Switzerland